Sanderling Biomedical Venture Capital

Website Links

Description

Founded in 1979, Sanderling is among the oldest investment firms dedicated to building new biomedical companies. Sanderling demonstrates that significant companies are best built in close working partnerships with entrepreneurs.

Timothy Mills has over twenty-five years of experience in biomedical research, corporate management and venture capital investing. Dr. Mills joined Sanderling as an Operating Partner in July 1998, and was promoted to Managing Director in 2000. At Sanderling, Dr. Mills has focused on early stage investments in Medical Devices, Biotherapeutics, and i-Health. His active roles within Sanderling’s portfolio companies include Chairman, CEO, Director, and management team member.

Regeneron was founded to develop neurotrophic factors for nerve repair and regeneration. The company therapeutic candidates in clinical trials for the potential treatment of obesity, rheumatoid arthritis, and cancer.

ReGen Biologics, Inc. is a biological remodeling company that develops and manufactures implants and medical devices for the regeneration and repair of tissue. Regen Biologics has a technology that is appropriate for a broad range of tissue regeneration applications.

In 1999, SkyePharma, Inc. acquired DepoTech Corporation, a company founded in conjunction with scientists from UC San Diego. Skyepharma has developed DepoFoamSM for injectable, controlled-release drug delivery. The lipid foam encapsulates a drug which, when injected, releases that drug over a predetermined period up to several months.

Companies nearby